Eurobio Scientific Presented New Breast Cancer Data at ESMO 2022

Eurobio Scientific presented findings from the European Society for Medical Oncology (ESMO) 2022 congress, highlighting the potential of the EndoPredict test in guiding chemotherapy treatment decisions. The company's industry satellite symposium featured insights led by Dr. Anastasia Constantinidou, focusing on research related to the EndoPredict test.

The presented research explored the use of EndoPredict in predicting metastasis and informing treatment choices for premenopausal women diagnosed with early-stage, hormone receptor-positive, HER2-negative breast cancer. According to the information shared, the test aims to help clinicians make informed decisions about chemotherapy, potentially avoiding overtreatment.

Dr. Constantinidou shared key data from the ESMO 2022 congress demonstrating how EndoPredict can guide treatment decisions and help avoid overtreatment in premenopausal women with ER+/HER2- early breast cancer. This approach seeks to optimize patient care by identifying those most likely to benefit from specific therapies, thereby improving outcomes and reducing unnecessary interventions.

Eurobio Scientific, a player in the in-vitro diagnostics sector, emphasizes the role of advanced diagnostic tools in clinical practice. Their focus lies in providing healthcare professionals with precise tools to support evidence-based decision-making in oncology.